Athira Pharma Q3 net loss $28.7M; LIFT-AD missed endpoints; exploring strategic alternatives

LeonaBio, Inc.

2024-Q3 EPS reported -$2.13

Net loss $28.7M ($0.75/sh) vs $33.0M ($0.87/sh) Q3 2023; cash $68.9M down from $147.4M at Dec 2023.
Fosgonimeton (ATH-1017) LIFT-AD Phase 2/3 missed primary and key secondary endpoints; development paused.
Exploring strategic alternatives with Cantor Fitzgerald; ATH-1105 Phase 1 healthy volunteers on track for year-end 2024.
R&D expenses $17.9M vs $27.2M; G&A $7.6M vs $7.8M; legal accrual $4.1M from DOJ investigation.
Plan to begin dosing ATH-1105 in ALS patients in 2025; preclinical data supports HGF-modulating mechanism.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.